CN111647083A - 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 - Google Patents
一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 Download PDFInfo
- Publication number
- CN111647083A CN111647083A CN202010350283.8A CN202010350283A CN111647083A CN 111647083 A CN111647083 A CN 111647083A CN 202010350283 A CN202010350283 A CN 202010350283A CN 111647083 A CN111647083 A CN 111647083A
- Authority
- CN
- China
- Prior art keywords
- variable region
- chain variable
- mouse anti
- human
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 58
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 102000000213 Hemojuvelin Human genes 0.000 claims description 62
- 108050008605 Hemojuvelin Proteins 0.000 claims description 62
- 239000002299 complementary DNA Substances 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 14
- 238000012163 sequencing technique Methods 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 210000004408 hybridoma Anatomy 0.000 claims description 10
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 238000013461 design Methods 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 238000002474 experimental method Methods 0.000 claims description 5
- 210000004988 splenocyte Anatomy 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002887 multiple sequence alignment Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229930014550 juvenile hormone Natural products 0.000 claims description 2
- 239000002949 juvenile hormone Substances 0.000 claims description 2
- 150000003633 juvenile hormone derivatives Chemical class 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000001742 protein purification Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 101000756823 Homo sapiens Hemojuvelin Proteins 0.000 description 9
- 102000052034 human HJV Human genes 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102100039879 Interleukin-19 Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 101000960946 Homo sapiens Interleukin-19 Proteins 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
抗体浓度 | OD值 | 抗体浓度 | OD值 | |
1 | 1.000000 | 3.276 | 0.007813 | 0.721 |
2 | 0.500000 | 3.187 | 0.003906 | 0.371 |
3 | 0.250000 | 3.122 | 0.001953 | 0.247 |
4 | 0.125000 | 2.887 | 0.000977 | 0.147 |
5 | 0.062500 | 2.525 | 0.000488 | 0.122 |
6 | 0.031250 | 1.899 | 0.000244 | 0.091 |
7 | 0.015625 | 1.15 | blank | 0.048 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010350283.8A CN111647083B (zh) | 2020-04-28 | 2020-04-28 | 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010350283.8A CN111647083B (zh) | 2020-04-28 | 2020-04-28 | 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111647083A true CN111647083A (zh) | 2020-09-11 |
CN111647083B CN111647083B (zh) | 2022-06-03 |
Family
ID=72345456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010350283.8A Active CN111647083B (zh) | 2020-04-28 | 2020-04-28 | 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111647083B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101307085A (zh) * | 2007-08-01 | 2008-11-19 | 钱忠明 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
AU2007322016A2 (en) * | 2006-11-17 | 2009-07-30 | Duke University | Multicomponent vaccine |
WO2014052393A2 (en) * | 2012-09-25 | 2014-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for the diagnosis and treatment of sjögren's syndrome |
US20140162295A1 (en) * | 2012-12-07 | 2014-06-12 | National Taiwan University | Method and Biomarker for Detecting of Acute Kidney Injury |
-
2020
- 2020-04-28 CN CN202010350283.8A patent/CN111647083B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007322016A2 (en) * | 2006-11-17 | 2009-07-30 | Duke University | Multicomponent vaccine |
CN101307085A (zh) * | 2007-08-01 | 2008-11-19 | 钱忠明 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
WO2014052393A2 (en) * | 2012-09-25 | 2014-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for the diagnosis and treatment of sjögren's syndrome |
US20140162295A1 (en) * | 2012-12-07 | 2014-06-12 | National Taiwan University | Method and Biomarker for Detecting of Acute Kidney Injury |
Also Published As
Publication number | Publication date |
---|---|
CN111647083B (zh) | 2022-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113150136B (zh) | 新型冠状病毒n蛋白单克隆抗体的制备 | |
WO2020125120A1 (zh) | 一种抗体文库的构建方法及其应用 | |
CN105112375A (zh) | 杂交瘤细胞株zjed0-02、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 | |
CN111647081B (zh) | 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 | |
CN112111006B (zh) | 抗牛结节性皮肤病病毒的抗体、检测试纸及试剂盒 | |
CN107383199B (zh) | 一种s-腺苷蛋氨酸合成酶的单克隆抗体及其应用 | |
CN105524173B (zh) | 一种针对人源抗体Fc片段的纳米抗体及其应用 | |
CN111647086B (zh) | 一种重组小鼠抗人肌酸激酶单克隆抗体、制备方法和应用 | |
CN114276445A (zh) | 轮状病毒重组蛋白特异性抗体、质粒载体及方法 | |
CN110872354B (zh) | 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 | |
CN111647083B (zh) | 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 | |
CN115838416A (zh) | 针对非洲猪瘟CD2v的抗体及其应用 | |
CN112679607B (zh) | 一种肌钙蛋白i e13单链抗体的制备方法 | |
CN108484770B (zh) | 重组大鼠抗小鼠cd4单克隆抗体,制备方法和应用 | |
CN113912728A (zh) | 降低抗人白介素-33单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 | |
CN105646712B (zh) | 单克隆抗体及其应用 | |
CN112342198A (zh) | PAT/pat单抗杂交瘤细胞株、产生的抗体及其制备方法 | |
WO2022121899A1 (zh) | 一种特异性结合Strep-Tag II标签的抗体及其应用 | |
CN115785277B (zh) | 一种抗IL4i1纳米抗体的制备及其应用 | |
CN117003880B (zh) | 抗硫氰酸荧光素单克隆抗体及其应用 | |
CN112094350B (zh) | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体 | |
CN114539403B (zh) | 靶向人bcma蛋白的兔重组单克隆抗体及应用 | |
CN113201069B (zh) | mcherry或mEOS纳米抗体及其制备方法和应用 | |
CN117143226B (zh) | 与hpv33型衣壳蛋白l1特异性结合的抗体或其抗原结合片段及其应用 | |
CN114773462B (zh) | 用于检测牛crp蛋白的重组单链抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240402 Address after: 430000 west of 3 / F, 21 / F (zone a), R & D building, No. 666, shendun Fourth Road, Donghu New Technology Development Zone, Wuhan, Hubei (Wuhan area of free trade zone) Patentee after: Wuhan Biyu Biotechnology Co.,Ltd. Country or region after: China Address before: Room 103, Building 1-4, Building C2, Phase 1.2, Guanggu Enterprise Mansion, No. 1 Guanshan Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430000 (178 #) Patentee before: Wuhan baijiekang Biotechnology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |